The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells
Open accessAbstract
The observation that TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine family, induces apoptosis in a number of different tumor cell types led us to compare the tumoricidal effects of TRAIL to those of other TNF family molecules on human melanoma cells. We found that a high proportion of the melanoma cell lines tested were killed by TRAIL, whereas all the melanoma lines were resistant to the other TNF family cytokines tested. TRAIL-induced death was characterized by caspase activation and cellular protein cleavage within minutes of TRAIL addition, and death could be completely inhibited by the caspase inhibitors Ile-Glu-Thr-Asp (IETD) and Val-Ala-Asp (VAD), indicating the presence of a TRAIL receptor signaling pathway similar to that identified for Fas and TNF receptors. Specific TRAIL receptor expression was determined by RT-PCR, and the presence of mRNA encoding the “protective” TRAIL receptors did not correspond to resistance or sensitivity to TRAIL-induced apoptosis. Addition of protein synthesis inhibitors to TRAIL-resistant melanomas rendered them sensitive to TRAIL, indicating that the presence or the absence of intracellular apoptosis inhibitors may mediate resistance or sensitivity to TRAIL-mediated apoptosis. Expression of one such inhibitor, FLICE-inhibitory protein (FLIP), was highest in the TRAIL-resistant melanomas, while being low or undetectable in the TRAIL-sensitive melanomas. Furthermore, addition of actinomycin D to TRAIL-resistant melanomas resulted in decreased intracellular concentrations of FLIP, which correlated with their acquisition of TRAIL sensitivity. Collectively, our results indicate that TRAIL-induced apoptosis occurs through a caspase signaling cascade and that resistance is controlled by intracellular regulators of apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Nicholson, D. W., & Thornberry, N. A. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01085-2 · Cited by 2,409
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Self-citationKaufmann, S. H., Desnoyers, S., Ottaviano, Y. L., Davidson, N. E., & Poirier, G. G. (1993) · PubMed · Cited by 1,889
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
The Biology Of Cachectin/TNF: A Primary Mediator Of The Host Response
Beutler, B. (1989) · Annual Review of Immunology · doi:10.1146/annurev.immunol.7.1.625 · Cited by 1,697
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F., et al. (1995) · Nature · doi:10.1038/373441a0 · Cited by 1,314
Self-citationProtease activation during apoptosis: Death by a thousand cuts?
Martin, S. J., & Green, D. R. (1995) · Cell · doi:10.1016/0092-8674(95)90422-0 · Cited by 1,309
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
Induction of apoptosis in mature T cells by tumour necrosis factor
Zheng, L., Fisher, G., Miller, R. E., Peschon, J., Lynch, D. H., & Lenardo, M. J. (1995) · Nature · doi:10.1038/377348a0 · Cited by 1,116
Self-citationA study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma
Clark, W. H., Elder, D. E., Guerry, D., Epstein, M. N., Greene, M. H., & Van Horn, M. (1984) · Human Pathology · doi:10.1016/s0046-8177(84)80310-x · Cited by 975
Fas ligand mediates activation-induced cell death in human T lymphocytes.
Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., & Lynch, D. H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.71 · Cited by 934
Self-citationDegli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Comparison of in vitro cell cytotoxic assays for tumor necrosis factor
Flick, D. A., & Gifford, G. E. (1984) · Journal of Immunological Methods · doi:10.1016/0022-1759(84)90147-9 · Cited by 745
Involvement of an ICE-like protease in Fas-mediated apoptosis
Enari, M., Hug, H., & Nagata, S. (1995) · Nature · doi:10.1038/375078a0 · Cited by 734
Fernandes-Alnemri, T., Armstrong, R. C., Krebs, J., Srinivasula, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7464 · Cited by 733
Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., & Hood, L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80400-8 · Cited by 711
TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB
Schneider, P., Thome, M., Burns, K., Bodmer, J.-L., Hofmann, K., Kataoka, T., Holler, N., & Tschopp, J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80401-x · Cited by 696
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas
Gruss, H., & Dower, S. (1995) · Blood · doi:10.1182/blood.v85.12.3378.bloodjournal85123378 · Cited by 450
Effect of bcl-2 on Fas antigen-mediated cell death.
Itoh, N., Tsujimoto, Y., & Nagata, S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.2.621 · Cited by 428
Bcl-XL and Bcl-2 repress a common pathway of cell death.
Chao, D. T., Linette, G. P., Boise, L. H., White, L. S., Thompson, C. B., & Korsmeyer, S. J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.821 · Cited by 395
The role of cachectin/TNF in endotoxic shock and cachexia
Ceramil, A., & Beutler, B. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91353-9 · Cited by 328
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
Tumor necrosis factor receptor superfamily members and their ligands
Armitage, R. J. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90119-8 · Cited by 299
Jäättelä, M., Benedict, M., Tewari, M., Ja, S., & Dixit, V. (1995) · PubMed · Cited by 289
Vincenz, C., & Dixit, V. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6578 · Cited by 256
Bcl-xLcan inhibit apoptosis in cells that have undergone Fas-induced protease activation
Boise, L. H., & Thompson, C. B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3759 · Cited by 221
Carpino, L. A., Cohen, B. J., Stephens, K. E., Sadat-Aalaee, S. Y., Tien, J. H., & Langridge, D. C. (1986) · The Journal of Organic Chemistry · doi:10.1021/jo00369a042 · Cited by 194
Wajant, H., Johannes, F., Haas, E., Siemienski, K., Schwenzer, R., Schubert, G., Weiß, T., Grell, M., & Scheurich, P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70042-9 · Cited by 144
Mongkolsapaya, J., Cowper, A., Xu, X., Morris, G. M., McMichael, A. J., Bell, J. I., & Screaton, G. R. (1998) · PubMed · Cited by 140
Grewal, I. S., & Flavell, R. A. (1997) · Immunologic Research · doi:10.1007/bf02786323 · Cited by 131
Mongkolsapaya, J., Cowper, A. E., Xu, X., Morris, G. M., McMichael, A. J., Bell, J. I., & Screaton, G. R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.3 · Cited by 116
Koopman, G., Keehnen, R. M. J., Lindhout, E., Zhou, D., Groot, C. D., & Pals, S. T. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270102 · Cited by 103
CD40 ligand inhibits Fas/CD95‐mediated apoptosis of human blood‐derived dendritic cells
Koppi, T. A., Tough‐Bement, T., Lewinsohn, D. M., Lynch, D. H., & Alderson, M. R. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271212 · Cited by 83
Self-citationRoman, C. A. J., Cherry, S. R., & Baltimore, D. (1997) · Immunity · doi:10.1016/s1074-7613(00)80506-3 · Cited by 80
Pathak, M. A. (2009) · Skin Pharmacology · doi:10.1159/000210987 · Cited by 64
Cited by
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationOverview of cell death signaling pathways
Jin, Z., & El-Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,326
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
TRAIL and apoptosis induction by TNF-family death receptors
Wang, S., & El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207232 · Cited by 871
Metadata
- Authors
- Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09
- Volume
- 161
- Issue
- 6
- Pages
- 2833-2840
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2098439946
- Cited by
- 664
- References
- 46
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.